RAAS inhibitors show benefits in pediatric CKD vs. CCBs

Renin-angiotensin-aldosterone system inhibitors were linked to better pediatric chronic kidney disease outcomes compared with calcium channel blockers, according to study data published in JAMA Pediatrics.
Renin-angiotensin-aldosterone system (RAAS) inhibitors and calcium channel blockers (CCBs) are two primary antihypertensive treatments used in the pediatric population, according to Michelle R. Denburg, MD, MSCE, associate professor of pediatrics (nephrology) at the Children’s Hospital of Philadelphia, and colleagues. However, few trials have compared the effectiveness of both


